Ekso Bionics Holdings, Inc. designs, develops, and markets exoskeleton products. Its exoskeleton technology serves multiple markets and can be utilized both by able-bodied persons and persons with physical disabilities or impairments. Its products include EksoNR, which is a wearable robotic exoskeleton specifically designed to be used in a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower-limb powered exoskeleton; Ekso Indego Personal is a lightweight powered lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton.
The Company enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate and to walk again; assist individuals with a range of upper extremity impairments and allow industrial workers to perform difficult repetitive work for extended periods.
Its segments include EksoHealth and EksoWorks..
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 140.9K | 
| Three Month Average Volume | 1.8M | 
| High Low | |
| Fifty-Two Week High | 3.1285 USD | 
| Fifty-Two Week Low | 0.62 USD | 
| Fifty-Two Week High Date | 02 Jan 2024 | 
| Fifty-Two Week Low Date | 08 Sep 2023 | 
| Price and Volume | |
| Current Price | 1.2 USD | 
| Beta | 1 | 
| Relative Price Change | |
| Four Week Relative Price Change | 13.59% | 
| Thirteen Week Relative Price Change | -2.50% | 
| Twenty-Six Week Relative Price Change | -45.16% | 
| Fifty-Two Week Relative Price Change | 6.37% | 
| Year-to-Date Relative Price Change | -59.47% | 
| Price Change | |
| One Day Price Change | 7.14% | 
| Thirteen Week Price Change | 4.35% | 
| Twenty-Six Week Price Change | -39.70% | 
| Five Day Price Change | 12.15% | 
| Fifty-Two Week Price Change | 33.29% | 
| Year-to-Date Price Change | -52.00% | 
| Month-to-Date Price Change | 14.29% | 
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.849 USD | 
| Book Value Per Share (Most Recent Quarter) | 0.65382 USD | 
| Tangible Book Value Per Share (Last Fiscal Year) | 0.4905 USD | 
| Tangible Book Value Per Share (Most Recent Quarter) | 0.37351 USD | 
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.63278 USD | 
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 1.31817 USD | 
| Revenue Per Share (Trailing Twelve Months) | 1.13203 USD | 
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD | 
| Dividend Per Share (Trailing Twelve Months) | 0 USD | 
| Dividend Per Share (5 Year) | -99999.99 USD | 
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.09598 USD | 
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.79092 USD | 
| Normalized (Last Fiscal Year) | -1.09598 USD | 
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.09598 USD | 
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.79092 USD | 
| Including Extraordinary Items (Last Fiscal Year) | -1.09598 USD | 
| Including Extraordinary Items (Trailing Twelve Months) | -0.79092 USD | 
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.58176 USD | 
| Cash Per Share (Most Recent Quarter) | 0.31907 USD | 
| Cash Flow Per Share (Last Fiscal Year) | -1.04363 USD | 
| Cash Flow Per Share (Trailing Twelve Months) | -0.66101 USD | 
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.69449 USD | 
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -96 | 
| Cash Flow Revenue (Trailing Twelve Months) | -61 | 
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -68.41% | 
| Pretax Margin (Last Fiscal Year) | -83.14% | 
| Pretax Margin (5 Year) | -104.24% | 
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 49.67% | 
| Gross Margin (Trailing Twelve Months) | 51.83% | 
| Gross Margin (5 Year) | 51.93% | 
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -82.67% | 
| Operating Margin (Trailing Twelve Months) | -66.52% | 
| Operating Margin (5 Year) | -112.80% | 
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -83.14% | 
| Net Profit Margin (Trailing Twelve Months) | -68.41% | 
| Net Profit Margin (5 Year) | -104.24% | 
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 5.49% | 
| Tangible Book Value (5 Year) | 23.46% | 
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% | 
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 5.25% | 
| Revenue Growth (3 Year) | 10.03% | 
| Revenue Change (Trailing Twelve Months) | 15.63% | 
| Revenue Per Share Growth | -13.84% | 
| Revenue Growth (5 Year) | 27.20% | 
| Capital Spending Debt | |
| Capital Spending (5 Year) | 3.69% | 
| Total Debt (5 Year) | 3.93% | 
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% | 
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 57.26% | 
| EPS Change (Trailing Twelve Months) | 34.69% | 
| EPS Growth (3 Year) | -99,999.99% | 
| EPS Growth (5 Year) | -99,999.99% | 
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% | 
| EBITDA (5 Year Interim) | -99,999.99% | 
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% | 
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 3 | 
| Price to Tangible Book (Most Recent Quarter) | 3 | 
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 | 
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 | 
| Net Debt | |
| Net Debt (Most Recent Quarter) | -283,000 | 
| Net Debt (Last Fiscal Year) | -2,556,000 | 
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 1 | 
| Price to Sales (Trailing Twelve Months) | 1 | 
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 | 
| PE Normalized (Last Fiscal Year) | -100,000 | 
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 | 
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 | 
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 | 
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 | 
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% | 
| Dividend Yield | -99,999.99% | 
| Current Dividend Yield | 0.00% | 
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 | 
| Price to Book (Most Recent Quarter) | 2 | 
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 38 | 
| Long Term Debt to Equity (Most Recent Quarter) | 36 | 
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% | 
| Payout Ratio (Trailing Twelve Months) | -99,999.99% | 
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 2 | 
| Quick Ratio (Most Recent Quarter) | 2 | 
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 | 
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 | 
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 2 | 
| Current Ratio (Most Recent Quarter) | 2 | 
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -12,211,000 | 
| Free Cash Flow (Trailing Twelve Months) | -11,141,000 | 
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 | 
| Net Interest Coverage (Trailing Twelve Months) | -24 | 
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 48 | 
| Total Debt to Equity (Most Recent Quarter) | 46 | 
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -43.53% | 
| Return on Assets (Trailing Twelve Months) | -40.75% | 
| Return on Assets (5 Year) | -43.63% | 
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -79.89% | 
| Return on Equity (Trailing Twelve Months) | -83.20% | 
| Return on Equity (5 Year) | -84.64% | 
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -57.89% | 
| Return on Investment (Trailing Twelve Months) | -57.60% | 
| Return on Investment (5 Year) | -57.67% |